SCHEMBL22227191

SCHEMBL22227191

COC(=O)c1ccc2c(c1)OCCCN2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
ALOX5 P09917 1/20 0.43
PIR O00625 1/20 0.41
GSK3B P49841 1/20 0.41
HSF1 Q00613 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 3/20 0.41
MAPT P10636 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30874422 1.00 NPC1 (0.44) NPC1RAB9ATDP1ALOX5PIR
SCHEMBL22225987 0.96 NPC1 (0.44) NPC1RAB9ATDP1ALOX5PIR
SCHEMBL31084560 0.92 ALOX5 (0.45) NPC1RAB9ATDP1ALOX5SMN1; SMN2
SCHEMBL304837 0.92 ALOX5 (0.45) NPC1RAB9ATDP1ALOX5SMN1; SMN2
SCHEMBL22225992 0.82 MAPT (0.56) NPC1RAB9ATDP1ALOX5PIR
SCHEMBL22207521 0.81 CYP2C9 (0.41) NPC1RAB9ATDP1PIRGSK3B
SCHEMBL31750464 0.80 ALDH1A1 (0.54) NPC1RAB9AALOX5SMN1; SMN2CASP3
SCHEMBL751823 0.80 ALDH1A1 (0.54) NPC1RAB9AALOX5SMN1; SMN2CASP3
SCHEMBL29940141 0.80 ALDH1A1 (0.54) NPC1RAB9AALOX5SMN1; SMN2CASP3
SCHEMBL22227204 0.80 MAPT (0.56) NPC1RAB9ATDP1ALOX5PIR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577217-B2 15-PGDH inhibitor KYORIN PHARMACEUTICAL CO., LTD. (JP) 2026-03-17 US disclosed
CN-113226310-B 15-PGDH inhibitors 杏林制药株式会社 2024-03-19 CN disclosed
US-20230082516-A1 15-PGDH INHIBITOR KYORIN PHARMACEUTICAL CO., LTD. (JP) 2023-03-16 US disclosed
EP-3922247-A1 15-PGDH INHIBITOR Kyorin Pharmaceutical Co., Ltd. (JP) 2021-12-15 EP disclosed
CN-113226310-A 15-PGDH inhibitors 杏林制药株式会社 2021-08-06 CN disclosed
WO-2020145250-A1 15-PGDH INHIBITOR 杏林製薬株式会社 2020-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230082516-A1 15-PGDH INHIBITOR UGDH, HPGD, GCDH NPC1 738/4885RAB9A 2665/4885TDP1 3854/4885
US-12577217-B2 15-PGDH inhibitor PTGDR, ADH1A, ADRA1A NPC1 1439/4885RAB9A 1847/4885TDP1 4197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.